全文获取类型
收费全文 | 104322篇 |
免费 | 46271篇 |
国内免费 | 263篇 |
专业分类
耳鼻咽喉 | 1930篇 |
儿科学 | 4825篇 |
妇产科学 | 1086篇 |
基础医学 | 18924篇 |
口腔科学 | 6562篇 |
临床医学 | 14846篇 |
内科学 | 31130篇 |
皮肤病学 | 7839篇 |
神经病学 | 16547篇 |
特种医学 | 3428篇 |
外国民族医学 | 1篇 |
外科学 | 18788篇 |
综合类 | 120篇 |
一般理论 | 28篇 |
预防医学 | 5473篇 |
眼科学 | 1803篇 |
药学 | 7149篇 |
中国医学 | 1070篇 |
肿瘤学 | 9307篇 |
出版年
2023年 | 357篇 |
2022年 | 301篇 |
2021年 | 2347篇 |
2020年 | 5739篇 |
2019年 | 11770篇 |
2018年 | 11216篇 |
2017年 | 12301篇 |
2016年 | 13049篇 |
2015年 | 12950篇 |
2014年 | 13156篇 |
2013年 | 13954篇 |
2012年 | 6785篇 |
2011年 | 6603篇 |
2010年 | 10323篇 |
2009年 | 6552篇 |
2008年 | 4157篇 |
2007年 | 3086篇 |
2006年 | 2937篇 |
2005年 | 2520篇 |
2004年 | 2304篇 |
2003年 | 2074篇 |
2002年 | 1902篇 |
2001年 | 841篇 |
2000年 | 706篇 |
1999年 | 323篇 |
1998年 | 230篇 |
1997年 | 197篇 |
1996年 | 154篇 |
1995年 | 166篇 |
1994年 | 143篇 |
1993年 | 123篇 |
1992年 | 164篇 |
1991年 | 137篇 |
1990年 | 113篇 |
1989年 | 89篇 |
1988年 | 111篇 |
1987年 | 88篇 |
1986年 | 81篇 |
1985年 | 92篇 |
1984年 | 76篇 |
1983年 | 54篇 |
1982年 | 55篇 |
1981年 | 37篇 |
1980年 | 38篇 |
1979年 | 54篇 |
1978年 | 40篇 |
1975年 | 34篇 |
1974年 | 29篇 |
1973年 | 54篇 |
1972年 | 40篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Marco N. Iannone Stefano Stucchi Elia A. Turolla Chiara Beretta Samuele Ciceri Clizia Chinello Lisa Pagani Sergio Todde Patrizia Ferraboschi 《Journal of labelled compounds & radiopharmaceuticals》2022,65(3):48-62
In the last decade, the development of new radiopharmaceuticals for the imaging and therapy of prostate cancer has been a highly active and important area of research, especially focusing on the prostate-specific membrane antigen (PSMA), an antigen which is upregulated in prostate, as well as in other tumor cells. A large variety of PSMA ligands have been radiolabeled, to date. Among the various derivatives, PSMA-617 resulted to be one of the most interesting in terms of interaction with the antigen and clinical properties, and its lutetium-177 labeled version has recently been approved by regulatory agencies for therapeutic purposes. For this reasons, the radiolabeling with fluorine-18 of a PSMA-617 derivative might be of interest. Beside other methodologies to radiolabel macromolecules with fluorine-18, the “click-chemistry” approach resulted to be very useful, and the copper-catalyzed azide-alkyne cycloaddition (CuAAC) is considered one of most efficient and reliable. This paper proposes the synthesis of a suitable precursor for the radiolabeling with fluorine-18 of a new PSMA-617 derivative. The whole radiosynthetic procedure has been fully automated, and the final product, which proved to be stable in plasma, has been obtained with radiochemical yield and purity suitable for subsequent preclinical studies. 相似文献
2.
3.
4.
5.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
6.
Mohammad Javad Alemzadeh‐Ansari Ali Sarreshtehdari Seifollah Abdi Jamal Moosavi Omid Shafe Parham Sadeghipour Hamidreza Pouraliakbar Bahram Mohebbi 《Seminars in dialysis》2021,34(1):89-93
A 70‐year‐old man with a history of coronary artery bypass grafting 15 years back and arteriovenous (AV) fistula creation in the left arm 1 month back presented with acute coronary syndrome (ACS). He had not received dialysis before his referral. We felt the most likely etiology for these complaints was increased cardiac oxygen demand from an increased cardiac output related to the newly formed left AV fistula. Coronary angiography was done to detect any significant stenosis in the native or grafted vessels. This revealed that the left subclavian artery was totally occluded in the ostioproximal segment and the coronary arteries did not have occlusions to explain the ACS setting. CT angiography confirmed the angiographic findings of the totally occluded left subclavian artery followed by a well‐developed and patent left internal mammary artery to left anterior descending artery. This led to the consideration of a steal syndrome from the coronary artery by the subclavian artery distal to the occlusion. A successful percutaneous endovascular intervention on the left subclavian artery occlusion was performed. Subsequently, the patient became asymptomatic and experienced a dramatic increase in left ventricular ejection fraction. 相似文献
7.
Monica Poiani Myriam Labopin Giorgia Battipaglia Dietrich W. Beelen Johanna Tischer Jürgen Finke Arne Brecht Edouard Forcade Arnold Ganser Jakob R. Passweg Helene Labussiere‐Wallet Ibrahim Yakoub‐Agha Kerstin Schfer‐Eckart Nicolaus Kroeger Blandine Guffroy Annalisa Ruggeri Jordi Esteve Arnon Nagler Mohamad Mohty 《American journal of hematology》2021,96(1):40-50
Karyotypic analysis at time of diagnosis has an important value in determining initial response to treatment, remission duration and overall survival (OS) in acute myeloid leukemia (AML). Less is known about its value before allogeneic hematopoietic cell transplantation (allo‐HCT) in patients transplanted with active disease, either relapsed or primary refractory (Rel‐Ref) AML. We explored the impact of cytogenetic risk (stratification according to MRC‐UK) in 2089 patients with either Ref (n = 972) or Rel AML (n = 1117) transplanted during the period 2000‐2017. Overall, 154 patients had a favorable risk, 1283 had an intermediate risk and 652 had an adverse cytogenetic risk. Median follow‐up was 49 months. Compared to the favorable risk group, intermediate and adverse risk patients were associated with worse leukemia‐free survival and OS and also with a higher incidence of relapse. In a subgroup analysis of patients in the intermediate risk group harboring Fms‐like tyrosine kinase 3‐internal tandem duplication (FLT3‐ITD), this remained an important prognostic factor, being associated with worse outcomes. When analyzing patients according to the intensity of the conditioning regimen, no differences were observed for the main transplant outcomes. In conclusion, in patients diagnosed with AML and transplanted with active disease, karyotype remains an important prognostic factor, allowing splitting patients into different risk groups according to their cytogenetics. Similarly, FLT3‐ITD mutation also remains a negative prognostic factor in this population. 相似文献
8.
9.
10.
Willy Baccaglini Felipe A. Glina Cristiano Linck Pazeto Luis G. Medina Fernando Korkes Wanderley M. Bernardo Rene Sotelo Sidney Glina Giancarlo Marra Marco Moschini Xavier Cathelineau Rafael Sanchez-Salas 《Clinical genitourinary cancer》2021,19(1):3-11.e1
This meta-analysis focuses on the accuracy of upgrading to clinically significant prostate cancer (PCa) by multiparametric magnetic resonance imaging-targeted biopsy (MRI-TB) versus systematic biopsy (SB). We searched the Medline, Embase, Cochrane Central Register of Controlled Trials, Web of Science, Scopus, and Literatura Latino Americana em Ciências da Saúde databases through January 2020 for comparative, retrospective/prospective, paired-cohort, and randomized clinical trials with paired comparisons. The population consisted of patients with low-risk PCa in active surveillance with at least 1 index lesion on imaging. We evaluated the quality of evidence by using the Quality Assessment of Diagnostic Accuracy Studies-2 score. Group comparisons considered the differences between the area under the curve summary receiver operating characteristic curve in a 2-tailed method. We also compared the positive predictive value of the best single method (MRI-TB or SB) and the referral study test (combined biopsy, a combination of MRI-TB and SB). The meta-analysis included 6 studies enrolling 741 patients. The pooled sensitivity for the 2 groups was 0.79 (95% confidence interval, 0.74-0.83; I2 = 75%) and 0.67 (95% confidence interval, 0.63-0.74; I2 = 55.4%), respectively. The area under the curve for the MRI-TB and SB groups were 0.99 and 0.92 (P < .001), respectively. The positive predictive value for the MRI-TB and combined biopsy groups were similar. The accumulated evidence suggests better results for MRI-TB compared with SB. Therefore, use of MRI-TB alone may be preferable in patients in active surveillance harboring low-risk PCa. 相似文献